BMRN vs REPL · P/E 40, rev $2.85B vs $825.7M cap
Biomarin Pharmaceutical Inc (BMRN) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
REPL does not have a complete income-statement cache yet.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. REPL currently screens at market cap $825.7M.
Not investment advice. Open the BMRN and REPL stock pages for the full models.
Not investment advice.